. 2019 Jul 5;10:2987. doi: 10.1038/s41467-019-10839-0

Table 1.

Treatment conditions of primary human lung fibroblasts

Compound	Final concentration	Solvent
GSK621	10 µM^a	DMSO
Metformin	1 mM, 5 mM,10 mM	DMEM
Nintedanib	1 µM^a	DMSO
Noggin	200 ng/mL	Noggin reconstitution buffer
Pirfenidone	0.3 mg/mL^a	Ethanol
Selumetinib	5 µM^a	DMSO
rhTGFβ1	2 ng/mL	rhTGFβ1 reconstitution buffer
rhBMP2	50 ng/mL^a	rhBMP2 reconstitution buffer

^aDosage was chosen based on a literature search and the dose showing highest efficacy was selected